VYNE Therapeutics (VYNE) 10-Q2021 Q1 Quarterly report

Filed: 6 May 21, 8:46am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: absent, accredited, barrier, Cantor, Caremark, CVS, dampened, Eastern, eighteen, FCD, fingolimod, Fitzgerald, FMX, fractional, inflammation, JAK, kinase, lieu, modulator, placement, propensity, Propionibacterium, proportionate, proportionately, rata, resistance, retrospectively, sphingosine, tofacitinib, umbrella, vaccination

Removed: abandon, accrue, accurate, activity, adversely, advisor, agreed, al, alleged, allegedly, allocating, alternatively, Andrew, approve, base, began, breach, breached, broker, called, carefully, case, chain, charged, chosen, collectively, commencing, commerce, compel, confirmed, consumer, contact, counsel, County, court, coverage, covered, CPI, CRO, dealer, declaration, deem, dependent, directing, dismissed, disrupt, disruption, disseminate, district, dividing, duty, education, employment, emulsion, enjoin, enrolled, essential, exact, expansion, expended, expert, explore, face, fact, failed, false, fiduciary, field, file, final, finance, foreign, guarantee, health, impair, implemented, index, individual, invalid, investigator, joined, joint, kind, laboratory, lawsuit, led, linked, local, macroeconomic, match, matching, Mateo, McKay, mediated, medical, misleading, mitigate, monetize, monitor, moot, negotiating, occurrence, operate, outlined, pathway, plaintiff, planning, predecessor, prejudice, presently, procuring, progression, prolonged, promulgated, proposal, proven, proxy, purported, pursued, randomized, raw, Redwood, registration, release, remedied, remote, removed, rendered, rescission, rescissory, resolution, resolve, respiratory, resumption, safeguard, Saik, San, selection, settlement, sought, speaker, speed, spread, strain, suffered, Superior, supporting, suspended, tangible, team, transparency, travel, Treasurer, unaware, unenforceable, unrealized, untrue, vast, vehicle, violated, violation, virtual, widespread, worldwide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated VYNE transcripts

VYNE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of VYNE Therapeutics Inc. (the “Company”), for the quarterly period ended March 31, 2021 as filed with the Securities and Exchange Commission (the “Report”), I, Andrew Saik, Chief Financial Officer, Treasurer and principal financial officer, hereby certify as of the date hereof, solely for purposes of 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 6, 2021	By:	/s/ Andrew Saik
		Andrew Saik Principal Financial Officer

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.